How to appeal a Blue Cross NC adult car-t cell therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross NC-specific note: BCBS licensee for North Carolina (~4.3M members). Prime Therapeutics PBM. NC DOI oversight. Blue Premier is the high-profile value-based care program. Recently divested some Medicaid business; Healthy Blue (joint venture with Elevance) handles NC Medicaid.

What Blue Cross NC's policy requires for adult car-t cell therapy

Cited policy: BCBS Federal Employee Program Medical Policy — Brexucabtagene Autoleucel (Tecartus)

FDA-approved indication: r/r mantle cell lymphoma after >=2 prior lines including a BTK inhibitor (Jul 2020 ZUMA-2) OR adult (>=18) r/r B-cell precursor ALL (Oct 2021 ZUMA-3). Age >=18. ECOG 0-1. ANC >=1000, plt >=75K, LVEF >=50%, CrCl >=60, AST/ALT <2.5x ULN, total bili <1.5. No active CNS disease. Administered at FACT-accredited REMS-certified ATC. Bridging + Flu/Cy LD bundled.

How Blue Cross NC denies adult car-t cell therapy — and how to counter it

Where Blue Cross NC pushes back: 1) 'Try allo-HSCT first' for adult B-ALL; 2) Prior BTKi requirement strict-interpretation for MCL; 3) MRD+ disease deemed insufficient.

Counter-arguments that hold up: ZUMA-2 (Wang NEJM 2020) — Tecartus 87% ORR / 62% CR in r/r MCL post-BTKi → FDA Jul 24 2020. ZUMA-3 (Shah Lancet 2021) — Tecartus 71% CR/CRi in adult r/r B-ALL → FDA Oct 1 2021. NCCN ALL v2.2024 + NCCN B-cell Lymphomas v6.2024 list Tecartus as preferred regimen. Allo-HSCT carries 20-30% TRM vs Tecartus much lower TRM; many B-ALL patients ineligible for allo-HSCT due to age/comorbidity/no donor. ZUMA-3 entry criteria included MRD+ relapse; MRD+ qualifies as r/r disease per NCCN + IWG. Prior BTKi requirement met by any covalent or non-covalent BTKi exposure.

What Blue Cross NC typically denies for adult car-t cell therapy

Across Blue Cross NC's commercial and Medicare books, denials cluster around a small number of patterns. For adult car-t cell therapy, expect:

• Step therapy via Prime Therapeutics
• Blue Premier value-based arrangement disputes
• Out-of-network reductions
• Specialty drug PA

Treatments most often denied in this category

These are the adult car-t cell therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Yescarta
• Kymriah
• Tecartus
• Breyanzi
• Carvykti
• Abecma

How to submit the appeal to Blue Cross NC

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross NC cited in the denial.
3. File the appeal through Blue Cross NC's portal (members: https://www.bluecrossnc.com ; providers: https://www.bluecrossnc.com/providers). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In NC, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross NC's prior-authorization criteria by drug: Blue Cross NC PA criteria on ApprovalHelp.